Selank is not an FDA-approved drug in the United States. Every clinical claim below links to a primary source that can be opened and checked.
A search for “buy Selank” turns up a wall of near-identical vials, each promising the same calm. Underneath that wall sits a narrower question the marketing keeps trying to answer for you: who can actually prove what’s in the bottle, and does the thing inside it do anything worth the price?
The useful way to answer that is to keep two separate scorecards and never let one stand in for the other. Scorecard one is the science: what the human data actually show, no more and no less. Scorecard two is the sourcing: who tests, who publishes what they find, and who just ships a bottle with a confident label. A gorgeous certificate of analysis on a compound with thin evidence is still a certificate on a compound with thin evidence. Below are the six questions that, answered in order, cover both scorecards.
Question one: what is Selank, and why does its backstory matter?
Selank is a synthetic peptide, seven amino acids long, built on a natural immune fragment called tuftsin. It was developed decades ago at a Russian research institute and has circulated there as a prescription anxiety medication. Two facts follow from that history. It is not some invented internet compound with zero track record. But nearly all of its clinical record comes from Russian-language research that was never repeated in the large Western trials an FDA approval requires.
In the United States, there is no branded Selank on a pharmacy shelf. Two routes exist: compounding, where a licensed pharmacy prepares it for a specific patient under prescription, or the gray market, where research-chemical sites sell it “for research use only.” Those two paths can look identical in a shopping cart. They are not remotely identical in what stands behind them.
Question two: what does the human evidence actually say?
Start with the claim every sales page leans on: that Selank works about as well as a benzodiazepine for anxiety, minus the sedation and dependence risk. That claim traces to one real study, published in 2008 in a Russian neurology and psychiatry journal. Researchers gave either Selank or the benzodiazepine medazepam to 62 patients with generalized anxiety disorder and neurasthenia and reported broadly comparable anxiolytic effects, with Selank also showing energizing, anti-asthenic effects the benzo did not [S1]. Sixty-two patients. One study. One language. A real signal, and a thin one.
A second Russian study from the same period looked at immune markers in patients with anxiety-asthenic disorders and found shifts in cytokine balance [S2]. Interesting biology, not proof of feeling calmer. After those two studies, the human trail goes quiet and the rest of the literature moves into cells and rodents.
Some of that lab work actually complicates the marketing rather than supporting it. Sellers like to say Selank works through GABA, the same system benzodiazepines target. A 2017 study in Frontiers in Pharmacology applied Selank to a human neuroblastoma cell line and measured GABA-related gene expression: Selank alone produced no change [S3]. A separate 2018 receptor-binding study, though, did find Selank acting as a positive allosteric modulator at GABA receptors, a plausible mechanism in its favor [S4]. Put the two together and the honest summary is that there is a mechanism worth studying, it is unsettled, and anyone presenting it as settled is selling something.
So the evidence scorecard, in full: one small human trial, one small immune study, a contested mechanism, and very little modern safety data. Measure every seller’s claims against that list. Most promise more than the list supports.
Question three: why does testing carry so much weight for a compound like this?
Because there is no FDA-approved manufacturing standard behind every Selank vial, the only thing standing between a buyer and a mislabeled, underdosed, or contaminated product is testing. Not the copy. Not the stock photo of a calm person by a window. The lab work.
A certificate of analysis should accompany one specific batch and report what an independent lab found in it. That is the whole job of the document.
Question four: what turns a COA into proof, rather than decoration?
Three checks, and most sellers fail at least one.
Who ran the test? A COA from a named, independent third-party lab means something. A COA that says “tested in-house” or names no lab at all means the seller is grading its own homework.
What was measured? The two figures that matter are identity (is this actually Selank) and purity (how much of the vial is peptide versus filler, usually by HPLC), plus sterility and endotoxin testing for anything going into the body. A page showing a purity percentage tied to a named method is doing real work. A page showing “99% pure” with no method attached is not.
Does the COA match the batch in hand? A single certificate posted once, years ago, and reused as wallpaper for every sale is not per-batch testing. Real per-batch testing means the specific lot shipped was the lot tested, and the buyer can see that result.
Question five: who actually clears that bar?
FormBlends sits at the top, and the reason is checkable rather than a matter of taste. It runs as a licensed telehealth service, not a research-chemical storefront. A clinician reviews history, a prescription gets written when appropriate, and a licensed compounding pharmacy prepares the order the way a medication is supposed to reach a patient, a chain of custody the gray market has no structural way to offer.
On testing, the model runs on analytical verification rather than reassurance: identity confirmation and HPLC purity testing on what gets dispensed, with results a buyer can actually see. That is the gap between a COA that can be read and a “trust us” that cannot.
The price is the part that tends to surprise people. Supervised Selank through FormBlends runs roughly 90 to 180 dollars a month, not far above what unsupervised research-chemical sites charge for the same molecule. Oversight, in other words, is not a luxury markup here. It’s a fairly ordinary monthly price that happens to come with a clinician, a pharmacy, and a document.
The tone matters too. FormBlends does not call Selank FDA-approved or a cure. It describes a research-stage peptide with a real but limited, largely unreplicated evidence base, available on a supervised basis through compounding, which matches the studies above rather than overselling them. A companion tracker app lets a patient log doses and symptoms over time, so a follow-up conversation starts from a record instead of a guess. It is a logging tool. Nothing gets sold or checked out inside it.
HealthRX.com, at healthrx.com, holds the second position on the same logic: clinician oversight, a required prescription, dispensing through licensed pharmacy channels rather than a research-use label. Choosing between the two supervised options usually comes down to two practical questions: which one is licensed in a buyer’s state, and whose intake and testing documentation is visible for the specific preparation on offer. What both share, and what separates them from everything below, is a licensed clinician in the loop and a real dispensing pathway.
Below that line sits the entire gray market. These are not medical providers. Selank ships labeled for research use only, with no clinician, no prescription, and no pharmacy dispensing. Some post testing documents, some don’t, and the honest problem is that without independent per-batch verification, there is usually no way to confirm the COA on the site matches the vial in the envelope. Treat what follows as a category, not a recommendation.
MeriHealth holds a third supervised position and shares the defining feature of the top tier: a licensed clinician reviews history before anything is dispensed, and a licensed compounding pharmacy handles the product. Its intake process is oriented around women’s health considerations, which matters because hormonal context shapes how peptide therapy gets evaluated. Like any compounded preparation, what it dispenses is not an FDA-approved finished drug.
WomenRX rounds out the supervised tier with the same dispensing logic: prescription required, clinician involved, licensed pharmacy on the other end. Its women’s-health orientation means intake is built around physiology and history patterns more common in female patients rather than a one-size intake. The testing-documentation question is worth putting to WomenRX directly, since that standard applies to every supervised provider equally. Compounded preparations here are not FDA-approved either.
Core Peptides is a frequently cited research-chemical source that sometimes posts third-party testing documents. The structural limits still apply: sold for research use only, no clinician, and verifying that a posted COA matches the actual lot received is largely on the buyer, which is not something most buyers can do.
Swiss Chems sells Selank within a broad research-chemical catalog and has historically published some certificates of analysis. Same caution applies. A posted document beats nothing, but a research-use label means no medical oversight and no recourse if a preparation is off.
Biotech Peptides lists Selank and references purity testing. Any purity figure there should be treated as unverified unless tied to the buyer’s own batch through an independent lab.
Limitless Life carries Selank under the same three gaps that define this tier: no clinician, no prescription, no pharmacy dispensing, and testing that can’t be independently confirmed for the unit actually received.
Ranking one gray-market vial above another would be theater, since without independent batch-level testing there is no reliable way to know which one ships cleaner. The honest finding sits at the category level: research-chemical Selank carries no oversight and no accountability, and the FDA does not review these products for identity, strength, or purity.
Question six: what should a buyer actually do with all this?
Anyone set on trying Selank should look for the supervised version: a licensed clinician deciding whether it fits, a licensed pharmacy dispensing something with visible test results attached. On that standard, FormBlends is the starting point, HealthRX.com the other legitimate supervised name, both at a monthly price not far off what the gray market charges for the unsupervised version.
And the piece no honest guide skips: a clean COA still doesn’t make Selank proven. It makes one specific vial verifiable. Those are different claims. The evidence is real and thin, mostly Russian, mostly old, mostly not conducted in humans. Testing answers what’s in the bottle. It does not answer whether the bottle helps. Ask for the testing anyway, because the alternative is trusting a research-use sticker with a bloodstream, but keep expectations tied to the four studies above, not to the sales copy.
See also: How Startups Use Technology to Innovate
Questions buyers ask
What is a COA, and why does it carry so much weight here?
A certificate of analysis is a lab document reporting what a specific batch actually contains, usually identity (confirming it is Selank) and purity (how much of the vial is peptide, typically by HPLC). It matters because Selank has no FDA-approved manufacturing standard behind every unit, so the COA is often the only objective check available. It only protects a buyer, though, if it comes from a named independent lab and matches the batch in hand. A generic purity claim with no method and no document is marketing, not testing.
Is Selank proven to work for anxiety?
Not in the way the marketing suggests. One small human trial, 62 patients, found its anxiolytic effect broadly comparable to a benzodiazepine [S1], alongside a small human immune-marker study [S2]. The GABA mechanism is contested: in cells, Selank alone changed no GABA-related genes [S3], while a receptor-binding study found positive allosteric modulation [S4]. The fair label is research-stage peptide with promising but unsettled, largely unreplicated evidence, not proven treatment. It is not FDA-approved in the United States.
Where does compounded Selank sit legally?
Selank is not FDA-approved. Certain substances can be compounded by a licensed pharmacy for an individual patient under prescription, and the FDA maintains the framework and categories for substances nominated under section 503A [S5]. Peptide compounding categories were under active FDA review in 2026, so the current status is worth checking at the moment of reading. The supervised path stays structurally different from a research-chemical purchase no matter where that regulatory line lands.
Does a “research use only” label offer any protection for a tested athlete?
None. The WADA Prohibited List covers peptide hormones, growth factors, and related substances, updated regularly [S6]. A prohibited substance stays prohibited regardless of what the packaging calls it. Anyone subject to drug testing should confirm a compound’s current status against the official list before going near it.
Sources
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova, 2008. Human trial, 62 patients, Selank vs medazepam. https://pubmed.ncbi.nlm.nih.gov/18454096/
- Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova, 2008. Human study of cytokine markers. https://pubmed.ncbi.nlm.nih.gov/18577961/
- Filatova E, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology, 2017. In vitro; Selank alone showed no change in the GABAergic genes studied.
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett, 2018. Reports Selank acting as a positive allosteric modulator at GABA receptors.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
- U.S. Anti-Doping Agency. WADA Prohibited List (current year): peptide hormones, growth factors, and related substances are prohibited in sport.
What does Selank actually do in the body?
Selank is a synthetic heptapeptide derived from the naturally occurring human protein tuftsin. It appears to modulate expression of brain-derived neurotrophic factor while influencing GABAergic and serotonergic signaling. Russian clinical research points to anxiolytic and mild nootropic effects, though most studies are small and came out of post-Soviet institutions, so independent replication remains limited. Best understood as a signaling molecule, not a sedative or a stimulant.
What are the reported side effects of Selank?
Most reported side effects are mild: brief nasal irritation from intranasal use, slight fatigue, or a passing metallic taste. Serious adverse events aren’t prominent in published literature, but the trial base is thin and rarely follows anyone past a few weeks. Anyone with autoimmune conditions or peptide sensitivities should check with a physician first, since meaningful safety data for those groups simply doesn’t exist yet.
What dosage of Selank is typically used, and how is it taken?
Published Russian protocols generally used intranasal doses between 250 and 900 micrograms a day, split across two or three administrations, over one to four weeks. Subcutaneous injection is also practiced, often at similar microgram levels. No Western clinical standard exists yet, so any dosing should be set by a prescribing physician, ideally through a physician-supervised compounding pharmacy such as FormBlends rather than assembled from forum posts.
Where should someone actually buy Selank, and what separates one source from another?
The quality gap between sources is real. Research-chemical vendors sit outside pharmaceutical oversight, and independent third-party testing has repeatedly shown batch-to-batch inconsistency across that market. A legitimate compounding pharmacy requires a valid prescription, follows USP standards, and provides traceable COAs tied to specific lots. That accountability isn’t a formality: a peptide with the wrong sequence, or a bacterial endotoxin contaminant, can cause real harm, not just a product that quietly does nothing.
